X4 Pharmaceuticals Inc XFOR

$2.75 +0.16 (6.18%)

Valuation

Market cap
256,791,000
Revenue TTM
$35,110,000
Net income TTM
$-79,200,000
PE ratio
0.00
Forward PE
—
Profit margin
-225.58%
Debt to equity
0.49

Trading

Volume
602,900
Avg volume
899,748
Day's range
$2.58 – $2.82
Shares out
99,147,000
Stochastic %K
60%
Beta
0.46
Analysts
Strong Sell
Price target
$11.60

Price

Company profile

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis s...

Show more

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
857 529 8300
Website
https://www.x4pharma.com
Address
61 North Beacon Street, 4th Floor, Boston, United States

Latest news

Stocktwits

UnlimitedWealth Oct 18, 4:42 PM
$XFOR Need to hold 2.50 level
0 replies
TwongStocks Oct 9, 11:18 AM
$XFOR X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders The Investor Day will feature discussions with X4 Pharmaceuticals management and key opinion leaders on mavorixafor as a potential treatment for chronic neutropenia. Management will review the current status of the Phase 3 4WARD clinical trial and will outline a planned Phase 2 clinical trial of mavorixafor in combination with granulocyte colony-stimulating factor (G-CSF), designed to assess patients' ability to titrate down their G-CSF dose while maintaining normal neutrophil counts. Oct 29 at 10:00am ET Webcast link https://x4-pharmaceuticals-investor-day-2026.open-exchange.net/registration
1 replies
focafoca99 Oct 8, 9:35 PM
$XFOR secured a $150M term loan agreement with K2 HealthVentures, funding an $80M tranche to repay existing debt.
0 replies
TwongStocks Oct 8, 11:13 AM
$XFOR X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures https://investors.x4pharma.com/news-releases/news-release-details/x4-pharmaceuticals-secures-150-million-senior-debt-facility-k2 They previously reported a cash runway into 2029. The first loan tranche of $80M will be used to pay off the Hercules loan. They have an additional $70M they can borrow from K2HV, which will likely be used to help fund the potential future commercial launch of mavorixafor in chronic neutropenia.
0 replies
809trader Oct 2, 11:07 AM
$XFOR finally coming back to daddy 🫶🔥
0 replies
1nvestorGadget Sep 26, 4:14 AM
$XFOR I posted a big piece on this before. This company today is fundamentally different vs. pre-2025 - and that starts with leadership. Paula Ragan (CEO) and Adam Mostafa (CFO) “Stepped down”, and the company has since shifted direction with a team that brings prior $CTIC experience. I discuss the successes of this new team in a post on my X account. That change is central to the thesis. Latest guidance reinforces the setup: • Cash runway through 2028 (no near-term dilution pressure) • Phase 3 (4WARD) enrollment on track for Q3 2026 • EU decision expected Q2 2026 (following positive opinion) • Commercial launch underway (early revenue ramp) In short: funded, progressing, and building. The upside case hinges on mavorixafor — particularly in chronic neutropenia (CN), where it has potential to become a meaningful (even blockbuster) asset. This is no longer the same risk profile the market is anchoring to.
1 replies
TwongStocks Sep 10, 6:22 PM
$XFOR Some interesting comments from Adam Craig today. https://event.summitcast.com/view/aMepMFxWv3z5SRZ9meKJzp/avk4X4LRbKukjcipVLXZ5g 1) He said when they first came onboard that they thought the 4WARD trial was overpowered. After having their statisticians review the trial, they concluded that they could run an adequately powered trial with only 126 patients. FDA agreed. 2) He also disclosed that they had issues with the previous CRO (Contract Research Organization) that was running the trial. They switched to Parexel. When he joined the company last year, the 4WARD trial did not have any US patients in the trial. With Parexel in place, they are seeing increased screenings and more US patients, which gives them confidence that they'll be able to complete enrollment later this year. 3) Once they finish enrollment later this year, they expect the last patient to reach 52 week follow up by end of next year. With topline data 8-12 weeks after that.
0 replies
TwongStocks Sep 9, 11:06 AM
$XFOR Updated Investor Presentation. I assume they will use this slide deck at the Wells Fargo Conference on Sept 10. https://investors.x4pharma.com/static-files/7f60a057-e0b6-45a9-ac0d-551568d6bad1 Slide 3: 4WARD Trial full enrollment expected in Q4 2026, topline expected in 1H 2028, potential approval in late 2028/early 2029. Slide 17: $208M as of June 30. 145.6m shares fully diluted. Cash runway into 2029.
1 replies